Glenmark Pharma shares gain on US FDA nod for acetaminophen, ibuprofen tabletsMoneycontrol • 5 days ago
Glenmark Pharmaceuticals Share Price | The share touched a 52-week high of Rs 1,095.95 and a 52-week low of Rs 516.65 on 25 April, 2024 and 26 April, 2023, respectively.
Share to Feed
As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Lupin is recalling 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market.
Lupin recalled 26,352 bottles of Rifampin capsules, used in the treatment of tuberculosis
KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1266 in its research report dated April 05, 2024.
Being passionate about derivative after a decade of struggle, Shilpa Rout, Derivative Lead Analyst and AVP – Research at Prabhudas Lilladher, suggests taking Bull Call spread on Nifty monthly expiry with buying 22,500 CE buy and selling 23,100 CE.
KR Choksey recommended Accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 984 in its research report dated February 22, 2024.
Glenmark Pharma formed bullish candlestick pattern on the daily scale with above average volumes. The stock showed nice recovery in last four days after falling closer to 200-day EMA, and now traded above all key moving averages.
The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement.
Priced at around Rs 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70 percent
Glenmark Pharma hit the highest level since 2017. The stock has formed long bullish candlestick pattern on the daily timeframe with strong volumes, and traded above all key moving averages.